JP2020506701A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506701A5 JP2020506701A5 JP2019541341A JP2019541341A JP2020506701A5 JP 2020506701 A5 JP2020506701 A5 JP 2020506701A5 JP 2019541341 A JP2019541341 A JP 2019541341A JP 2019541341 A JP2019541341 A JP 2019541341A JP 2020506701 A5 JP2020506701 A5 JP 2020506701A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- tissue
- molecule
- wnt
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013814 Wnt Human genes 0.000 claims 72
- 108050003627 Wnt Proteins 0.000 claims 72
- 108090000765 processed proteins & peptides Proteins 0.000 claims 60
- 229920001184 polypeptide Polymers 0.000 claims 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims 57
- 210000001519 tissue Anatomy 0.000 claims 44
- 230000011664 signaling Effects 0.000 claims 38
- 150000007523 nucleic acids Chemical group 0.000 claims 37
- 239000000556 agonist Substances 0.000 claims 33
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 29
- 210000004027 cell Anatomy 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000013598 vector Substances 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 108020004999 messenger RNA Proteins 0.000 claims 12
- 239000013604 expression vector Substances 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 102100026292 Asialoglycoprotein receptor 1 Human genes 0.000 claims 9
- 101710200897 Asialoglycoprotein receptor 1 Proteins 0.000 claims 9
- 102100026293 Asialoglycoprotein receptor 2 Human genes 0.000 claims 9
- 101710200901 Asialoglycoprotein receptor 2 Proteins 0.000 claims 9
- 101001038507 Homo sapiens Ly6/PLAUR domain-containing protein 3 Proteins 0.000 claims 9
- 101000835086 Homo sapiens Transferrin receptor protein 2 Proteins 0.000 claims 9
- 102100040281 Ly6/PLAUR domain-containing protein 3 Human genes 0.000 claims 9
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 claims 9
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 claims 9
- 102100026143 Transferrin receptor protein 2 Human genes 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 102000011799 Desmoglein Human genes 0.000 claims 8
- 108050002238 Desmoglein Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 108020004414 DNA Proteins 0.000 claims 7
- 108091006611 SLC10A1 Proteins 0.000 claims 7
- 102000054329 Solute carrier family 10 member 1 Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 210000000988 bone and bone Anatomy 0.000 claims 5
- 230000010354 integration Effects 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- 210000005228 liver tissue Anatomy 0.000 claims 5
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims 4
- 101710109241 E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims 4
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 230000004927 fusion Effects 0.000 claims 4
- 210000004400 mucous membrane Anatomy 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 3
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 3
- 241000711549 Hepacivirus C Species 0.000 claims 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 3
- 108091006207 SLC-Transporter Proteins 0.000 claims 3
- 102000037054 SLC-Transporter Human genes 0.000 claims 3
- 230000000968 intestinal effect Effects 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 239000011574 phosphorus Substances 0.000 claims 3
- 230000001720 vestibular Effects 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 102000004961 Furin Human genes 0.000 claims 2
- 108090001126 Furin Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- 101000802406 Homo sapiens E3 ubiquitin-protein ligase ZNRF3 Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000026062 Tissue disease Diseases 0.000 claims 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 2
- 101150010310 WNT-4 gene Proteins 0.000 claims 2
- 101150019524 WNT2 gene Proteins 0.000 claims 2
- 102000052547 Wnt-1 Human genes 0.000 claims 2
- 108700020987 Wnt-1 Proteins 0.000 claims 2
- 102000052556 Wnt-2 Human genes 0.000 claims 2
- 108700020986 Wnt-2 Proteins 0.000 claims 2
- 102000052549 Wnt-3 Human genes 0.000 claims 2
- 108700020985 Wnt-3 Proteins 0.000 claims 2
- 102000052548 Wnt-4 Human genes 0.000 claims 2
- 108700020984 Wnt-4 Proteins 0.000 claims 2
- -1 Wnt2B Proteins 0.000 claims 2
- 102000044880 Wnt3A Human genes 0.000 claims 2
- 108700013515 Wnt3A Proteins 0.000 claims 2
- 101100485097 Xenopus laevis wnt11b gene Proteins 0.000 claims 2
- 102000006083 ZNRF3 Human genes 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003027 ear inner Anatomy 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 210000003780 hair follicle Anatomy 0.000 claims 2
- 210000005003 heart tissue Anatomy 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000005075 mammary gland Anatomy 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 210000004923 pancreatic tissue Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 210000005084 renal tissue Anatomy 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000001779 taste bud Anatomy 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 claims 1
- 101710094892 Furin-1 Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 102000037126 Leucine-rich repeat-containing G-protein-coupled receptors Human genes 0.000 claims 1
- 108091006332 Leucine-rich repeat-containing G-protein-coupled receptors Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 102100022762 R-spondin-1 Human genes 0.000 claims 1
- 101710110302 R-spondin-1 Proteins 0.000 claims 1
- 102100022763 R-spondin-2 Human genes 0.000 claims 1
- 101710110295 R-spondin-2 Proteins 0.000 claims 1
- 102100022766 R-spondin-3 Human genes 0.000 claims 1
- 101710110310 R-spondin-3 Proteins 0.000 claims 1
- 102100022759 R-spondin-4 Human genes 0.000 claims 1
- 101710110307 R-spondin-4 Proteins 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000002155 anti-virotic effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000012202 endocytosis Effects 0.000 claims 1
- 201000007089 exocrine pancreatic insufficiency Diseases 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002200 mouth mucosa Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 235000004400 serine Nutrition 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 235000008521 threonine Nutrition 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023057334A JP7635291B2 (ja) | 2017-01-26 | 2023-03-31 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| JP2024195763A JP2025020347A (ja) | 2017-01-26 | 2024-11-08 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450804P | 2017-01-26 | 2017-01-26 | |
| US62/450,804 | 2017-01-26 | ||
| US201762487135P | 2017-04-19 | 2017-04-19 | |
| US62/487,135 | 2017-04-19 | ||
| PCT/US2018/015595 WO2018140821A1 (en) | 2017-01-26 | 2018-01-26 | Tissue-specific wnt signal enhancing molecules and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023057334A Division JP7635291B2 (ja) | 2017-01-26 | 2023-03-31 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506701A JP2020506701A (ja) | 2020-03-05 |
| JP2020506701A5 true JP2020506701A5 (enExample) | 2021-02-25 |
| JP7305543B2 JP7305543B2 (ja) | 2023-07-10 |
Family
ID=62978866
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541341A Active JP7305543B2 (ja) | 2017-01-26 | 2018-01-26 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| JP2023057334A Active JP7635291B2 (ja) | 2017-01-26 | 2023-03-31 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| JP2024195763A Pending JP2025020347A (ja) | 2017-01-26 | 2024-11-08 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023057334A Active JP7635291B2 (ja) | 2017-01-26 | 2023-03-31 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| JP2024195763A Pending JP2025020347A (ja) | 2017-01-26 | 2024-11-08 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11958891B2 (enExample) |
| EP (1) | EP3574019A4 (enExample) |
| JP (3) | JP7305543B2 (enExample) |
| CN (1) | CN110234662A (enExample) |
| AU (1) | AU2018211985B2 (enExample) |
| CA (1) | CA3050133A1 (enExample) |
| WO (1) | WO2018140821A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3568158A4 (en) | 2017-01-11 | 2020-11-18 | The Board of Trustees of the Leland Stanford Junior University | R-SPONDIN SUBSTITUTION MOLECULES (RSPO) |
| CN110234662A (zh) | 2017-01-26 | 2019-09-13 | 瑟罗泽恩公司 | 组织特异性wnt信号增强分子和其用途 |
| AU2018393074B2 (en) | 2017-12-19 | 2025-10-23 | Surrozen Operating, Inc. | Anti-frizzled antibodies and methods of use |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| EP3820499A4 (en) | 2018-07-09 | 2022-07-13 | Surrozen Operating, Inc. | TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES |
| WO2020139950A1 (en) * | 2018-12-27 | 2020-07-02 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Bispecific antibody for membrane clearance of target receptors |
| CA3129155A1 (en) * | 2019-02-11 | 2020-08-20 | Surrozen, Inc. | Modulation of wnt signalling in ocular disorders |
| US20220175884A1 (en) * | 2019-04-02 | 2022-06-09 | Surrozen Operating, Inc. | Modulation of wnt signaling in auditory disorders |
| KR20220024460A (ko) * | 2019-06-11 | 2022-03-03 | 안틀라 테라퓨틱스 아이엔씨. | 다가 fzd 및 wnt 결합 분자 및 이의 용도 |
| CA3141632A1 (en) | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors |
| KR102192471B1 (ko) * | 2019-10-18 | 2020-12-17 | 주식회사 인코스팜 | 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물 |
| US20240000890A1 (en) * | 2020-01-09 | 2024-01-04 | Retinal Solutions, LLC | Neural regeneration with synthetic protein administration |
| WO2021173726A1 (en) * | 2020-02-24 | 2021-09-02 | Surrozen, Inc. | Wnt super agonists |
| KR20230107301A (ko) * | 2020-11-10 | 2023-07-14 | 더 스크립스 리서치 인스티튜트 | 오피오이드 치료들을 위한 항체들 |
| WO2022104280A1 (en) * | 2020-11-16 | 2022-05-19 | Surrozen Operating, Inc. | Liver-specific wnt signal enhancing molecules and uses thereof |
| CN112386687B (zh) * | 2020-12-09 | 2021-05-04 | 爱龄医美国际健康咨询服务(北京)有限公司 | 一种干细胞外泌体及其在药品和化妆品中的应用 |
| CN113307882B (zh) * | 2021-05-12 | 2022-12-20 | 东北大学 | 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物 |
| CN113293214A (zh) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | 一种检测神经母细胞瘤复发转移基因wnt2扩增的引物探针及其应用 |
| CA3225626A1 (en) * | 2021-07-15 | 2023-01-19 | Diogenx | Recombinant variants of r-spondin proteins and their use |
| JPWO2023080159A1 (enExample) * | 2021-11-02 | 2023-05-11 | ||
| CN116789843B (zh) * | 2022-03-16 | 2024-09-17 | 伯桢生物科技(杭州)有限公司 | Wnt重组蛋白及其应用 |
| CN116836274B (zh) * | 2022-03-23 | 2024-11-22 | 东莞市朋志生物科技有限公司 | 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒 |
| CA3258980A1 (en) * | 2022-06-21 | 2023-12-28 | Surrozen Operating, Inc. | WNT SIGNALING MODULATION IN CORNEAL DISORDERS |
| WO2025146152A1 (zh) * | 2024-01-04 | 2025-07-10 | 上海宝济药业股份有限公司 | 一种药物组合物及其应用 |
| CN120647751B (zh) * | 2025-08-18 | 2025-12-02 | 成都迈科康生物科技有限公司 | 抗人乳头瘤病毒e1蛋白的抗体或其试剂盒和相关应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| WO2005040418A2 (en) | 2003-10-10 | 2005-05-06 | Deutsches Krebsforschungszentrum | Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt |
| DE102004050620A1 (de) | 2004-10-13 | 2006-04-20 | Eberhard-Karls-Universität Tübingen | Monoklonaler Antikörper gegen Frizzled-Rezeptoren |
| DE102005035568A1 (de) | 2005-07-25 | 2007-02-01 | M-Phasys Gmbh | Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns |
| EP4174179B1 (en) | 2005-08-23 | 2025-05-07 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| EP2044123B1 (en) | 2006-06-21 | 2013-03-13 | Oncotherapy Science, Inc. | Tumor-targeting monoclonal antibodies to fzd10 and uses thereof |
| JP5317697B2 (ja) | 2006-08-14 | 2013-10-16 | 中外製薬株式会社 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| WO2008093646A1 (ja) * | 2007-02-01 | 2008-08-07 | National University Corporation NARA Institute of Science and Technology | Wntシグナル伝達系活性化ペプチド |
| TWI506037B (zh) | 2008-09-26 | 2015-11-01 | Oncomed Pharm Inc | 捲曲結合劑類及彼等之用途 |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| PL2393917T3 (pl) | 2009-02-03 | 2016-12-30 | Podłoże do hodowli nabłonkowych komórek macierzystych i organoidów zawierających komórki macierzyste | |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| US9042340B2 (en) | 2009-02-10 | 2015-05-26 | Nokia Corporation | Method, apparatus and computer program product for transfer of capability support information in a multi-rat environment |
| EP2305274A1 (en) * | 2009-09-21 | 2011-04-06 | Centre National de la Recherche Scientifique (CNRS) | Use of WNT stimulators for treating demyelinating diseases |
| TWI488642B (zh) | 2009-12-09 | 2015-06-21 | Bayer Schering Pharma Ag | 抗－Ｃ４．４ａ抗體及其用途 |
| CN102971337B (zh) | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| EP3072961A1 (en) | 2010-04-16 | 2016-09-28 | Children's Medical Center Corporation | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| EP4108671B1 (en) | 2010-10-01 | 2024-11-20 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| AU2012234335B2 (en) | 2011-03-29 | 2016-09-01 | Roche Glycart Ag | Antibody Fc variants |
| WO2012138453A1 (en) | 2011-04-03 | 2012-10-11 | The General Hospital Corporation | Efficient protein expression in vivo using modified rna (mod-rna) |
| GB201106395D0 (en) * | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| PL3682905T3 (pl) | 2011-10-03 | 2022-04-04 | Modernatx, Inc. | Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania |
| CN109111523B (zh) * | 2011-10-14 | 2022-06-07 | 诺华股份有限公司 | 用于Wnt途径相关疾病的抗体和方法 |
| WO2013071047A1 (en) | 2011-11-11 | 2013-05-16 | Children's Medical Center Corporation | Compositions and methods for in vitro transcription of rna |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| CN104302782A (zh) * | 2012-02-28 | 2015-01-21 | 诺华股份有限公司 | 利用rnf43突变状态选择wnt信号转导抑制剂给药的癌症患者 |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| MX2015001678A (es) | 2012-08-09 | 2015-08-14 | Roche Glycart Ag | Anticuerpos asgpr y sus usos. |
| US20150307542A1 (en) | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
| HK1220122A1 (zh) | 2013-03-09 | 2017-04-28 | Modernatx, Inc. | Mrna的异源未转录区域 |
| WO2015164392A2 (en) | 2014-04-21 | 2015-10-29 | Stemcentrx, Inc. | Novel antii-rnf43 antibodies and methods of use |
| WO2016040895A1 (en) | 2014-09-12 | 2016-03-17 | xxTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | Wnt signaling agonist molecules |
| SG11201703403TA (en) | 2014-10-27 | 2017-05-30 | Agency Science Tech & Res | Anti-tim-3 antibodies |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| CN107250158B (zh) | 2014-11-19 | 2022-03-25 | 基因泰克公司 | 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法 |
| MA45420A (fr) * | 2015-04-17 | 2019-05-01 | Merrimack Pharmaceuticals Inc | Traitements combinés avec seribantumab |
| DK3365373T3 (da) * | 2015-10-23 | 2021-04-06 | Merus Nv | Bindingsmolekyler, der hæmmer cancervækst |
| CA3006460A1 (en) | 2015-12-08 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| US20170349659A1 (en) | 2016-06-03 | 2017-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Wnt signaling agonist molecules |
| WO2018107116A1 (en) | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| EP3568158A4 (en) * | 2017-01-11 | 2020-11-18 | The Board of Trustees of the Leland Stanford Junior University | R-SPONDIN SUBSTITUTION MOLECULES (RSPO) |
| CN110234662A (zh) | 2017-01-26 | 2019-09-13 | 瑟罗泽恩公司 | 组织特异性wnt信号增强分子和其用途 |
| WO2018203567A1 (en) | 2017-05-02 | 2018-11-08 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| GB201708330D0 (en) | 2017-05-24 | 2017-07-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Fusion protein for enhancing intestinal regeneration |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| AU2018393074B2 (en) | 2017-12-19 | 2025-10-23 | Surrozen Operating, Inc. | Anti-frizzled antibodies and methods of use |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| CA3104526A1 (en) | 2018-07-05 | 2020-01-09 | Surrozen, Inc. | Multi-specific wnt surrogate molecules and uses thereof |
| EP3820499A4 (en) | 2018-07-09 | 2022-07-13 | Surrozen Operating, Inc. | TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES |
| WO2020132356A1 (en) | 2018-12-19 | 2020-06-25 | Surrozen, Inc. | Antigen binding formats for receptor complexes |
| CA3129155A1 (en) | 2019-02-11 | 2020-08-20 | Surrozen, Inc. | Modulation of wnt signalling in ocular disorders |
| EP3938036A4 (en) | 2019-03-11 | 2023-06-28 | Surrozen Operating, Inc. | Modulation of wnt signaling in gastrointestinal disorders |
| US20220175884A1 (en) | 2019-04-02 | 2022-06-09 | Surrozen Operating, Inc. | Modulation of wnt signaling in auditory disorders |
| KR20220024460A (ko) | 2019-06-11 | 2022-03-03 | 안틀라 테라퓨틱스 아이엔씨. | 다가 fzd 및 wnt 결합 분자 및 이의 용도 |
| US11050604B2 (en) | 2019-07-01 | 2021-06-29 | Rampart Communications, Inc. | Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation |
| WO2021173726A1 (en) | 2020-02-24 | 2021-09-02 | Surrozen, Inc. | Wnt super agonists |
| WO2022104280A1 (en) | 2020-11-16 | 2022-05-19 | Surrozen Operating, Inc. | Liver-specific wnt signal enhancing molecules and uses thereof |
| WO2022192445A1 (en) | 2021-03-10 | 2022-09-15 | Surrozen Operating, Inc. | Modulation of wnt signaling in gastrointestinal disorders |
-
2018
- 2018-01-26 CN CN201880008831.XA patent/CN110234662A/zh active Pending
- 2018-01-26 JP JP2019541341A patent/JP7305543B2/ja active Active
- 2018-01-26 EP EP18744610.9A patent/EP3574019A4/en active Pending
- 2018-01-26 AU AU2018211985A patent/AU2018211985B2/en active Active
- 2018-01-26 US US16/481,001 patent/US11958891B2/en active Active
- 2018-01-26 WO PCT/US2018/015595 patent/WO2018140821A1/en not_active Ceased
- 2018-01-26 CA CA3050133A patent/CA3050133A1/en active Pending
-
2023
- 2023-03-31 JP JP2023057334A patent/JP7635291B2/ja active Active
-
2024
- 2024-03-06 US US18/597,679 patent/US20240279303A1/en active Pending
- 2024-11-08 JP JP2024195763A patent/JP2025020347A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506701A5 (enExample) | ||
| JP2023078467A5 (enExample) | ||
| JP7635291B2 (ja) | 組織特異的Ｗｎｔシグナル増強分子およびその使用 | |
| US12466884B2 (en) | Tissue-specific WNT signal enhancing molecules and uses | |
| JPWO2020014271A5 (enExample) | ||
| CN103687946B (zh) | 用于诱导组织再生的肽及其应用 | |
| EP3319633B1 (en) | Vaccine against rsv | |
| RU2014144309A (ru) | Индазольные ингибиторы сигнального пути wnt и их терапевтические применения | |
| JP2008505190A5 (enExample) | ||
| WO2008109155A3 (en) | Compositions and methods for treatment of cervical cancer | |
| CN113194978B (zh) | 具有间充质干细胞的动员活性的肽 | |
| CN101679484A (zh) | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 | |
| CN103998462A (zh) | Wnt组合物及此类组合物的治疗应用 | |
| JP2011530599A5 (enExample) | ||
| JP2016514100A5 (enExample) | ||
| CN105934249A (zh) | 用于治疗肺高压的组合物和方法 | |
| TW200844231A (en) | Vectors for multiple gene expression | |
| JP2017521074A5 (enExample) | ||
| RU2013111835A (ru) | Дикетоны и гидроксикетоны в качестве активатора сигнального пути катенина | |
| JPH06502538A (ja) | 上皮細胞成長因子（ｅｇｆ）との相同性をもつヘパリン結合性マイトジェン | |
| CN1962865A (zh) | 人sfrp1基因、其编码蛋白及应用 | |
| JP2007536910A5 (enExample) | ||
| Sonavane et al. | Controlling Wnt signaling specificity and implications for targeting WNTs pharmacologically | |
| CN102732524B (zh) | 类HRG的七鳃鳗Lj-RGD3全RGD缺失突变体Lj-112在抗肿瘤药物中的应用 | |
| JP2020526202A5 (enExample) |